Market News & Trends
Niagara University Faculty Present Groundbreaking Research, New Insulin Pill For Diabetes Patients
NIAGARA UNIVERSITY, N.Y. - The need for painful insulin injections by certain diabetes patients may be eliminated with the introduction of a new technique…
Aptar Pharma Announces Development & License Agreement With BD
Aptar Pharma Announces Development & License Agreement With BD Aptar Pharma, a leading drug delivery solutions provider and segment of AptarGroup, Inc.…
Results From Preclinical Research & Phase Ib Study of Biogen’s Investigational Alzheimer’s Disease Treatment Published
Results from preclinical research and PRIME, the Phase Ib study of Biogen’s investigational treatment for early Alzheimer’s disease (AD), aducanumab, were published in a recent…
SteadyMed Announces Completion of Pre-NDA Submission Manufacturing Activities
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery…
SGS Opens New Dedicated Facility for Extractables & Leachables Testing
SGS, a leading bio/pharmaceutical analytical and bioanalytical contract solutions provider, recently announced it has opened a new facility in Wiesbaden, Germany, exclusively to offer extractables…
Dalton Announces Completion of a Major Expansion in Sterile Filling & API Manufacturing
Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical and biotechnology companies, recently announced the completion of a $5-million expansion in…
Cytokinetics & Amgen to Advance Drug to Phase III Clinical Development
Cytokinetics, Inc. recently announced the advancement of omecamtiv mecarbil to Phase III clinical development with a cardiovascular outcomes clinical trial expected to initiate in the…
Avantor Performance Materials & NuSil Technology to Merge
Avantor Performance Materials and NuSil Technology LLC, both portfolio companies of New Mountain Capital LLC, have signed a definitive agreement to merge. This merger will…
CordenPharma Chenôve Receives Successful FDA Inspection
CordenPharma is pleased to announce that their CordenPharma Chenôve (France) manufacturing facility recently completed an FDA Inspection and received a successful response with no…
Hemispherx Biopharma Announces Major Breakthrough
Hemispherx Biopharma, Inc. recently announced it has received approval of its New Drug Application (NDA) from Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT)…
BioTelemetry Agrees to License Proprietary Technology to Bloom Technologies
BioTelemetry, Inc. recently announced it has entered into a strategic partnership with Bloom Technologies, Inc. Under the terms of the agreement, Bloomlife will pay BioTelemetry…
BioPharmX Enrolls First Subject in OPAL Phase IIb Clinical Trial
BioPharmX Corporation recently announced that the first subject has been enrolled in its Phase IIb clinical trial assessing the efficacy and safety of BPX-01 for…
Novel Gene Therapy Drug for Huntington's Disease Reported
Data from Vybion on a novel treatment for Huntington's disease has been published in the Journal of Neurodegenerative diseases. The published study (http://www.hindawi.com/journals/jnd/2016/7120753/) links the…
Stemline Therapeutics Receives Breakthrough Therapy Designation
Stemline Therapeutics, Inc. recently announced that the US FDA has granted Breakthrough Therapy Designation to SL-401, a targeted therapy directed to the interleukin-3 receptor (CD123),…
Idera Pharmaceuticals Presents Novel Mechanism of Action of its Third- Generation Antisense Technology
Idera Pharmaceuticals, Inc. recently announced the presentation of new preclinical data that demonstrates the novel gene-silencing mechanism of action of the third-generation antisense (3GA) technology…
AMRI Licenses CRISPR-Cas9 Gene Editing Technology
AMRI recently announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9…
Cell Medica & University College London Collaborate to Develop Modified T Cell Receptor Products for the Treatment of Cancer
Cell Medica (the Company) announces a new research collaboration with UCL (University College London) which will see the Company utilize UCL’s novel T cell receptor (TCR)…
AMRI Licenses CRISPR-Cas9 Gene Editing Technology
AMRI recently announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9…
Cell Medica & University College London Collaborate to Develop Modified T Cell Receptor Products for the Treatment of Cancer
Cell Medica (the Company) announces a new research collaboration with UCL (University College London) which will see the Company utilize UCL’s novel T cell receptor (TCR)…
Female Health Company & Aspen Park Pharmaceuticals Announce FDA Clears Pathway
The Female Health Company (FHC) and Aspen Park Pharmaceuticals, Inc. (APP) recently announced that the US FDA has agreed to an expedited regulatory pathway for…
